Navigation Links
Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
Date:12/10/2013

trong or moderate inhibitors of CYP3A. If a moderate CYP3A inhibitor must be used, reduce the IMBRUVICA dose.

CYP3A Inducers - Avoid co-administration with strong CYP3A inducers.

SPECIAL POPULATIONS - Hepatic Impairment - Avoid use in patients with baseline hepatic impairment.

Because everyone is different, it is not possible to predict what side effects any one patient will have. Patients with questions or concerns about side effects should talk to their doctor.

Report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch.

For more information please read the IMBRUVICA Full Prescribing Information at www.IMBRUVICA.com.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements, including our expected liquidity position and timing of the receipt of certain milestone payments, and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "goal", "should", "would", "project", "plan", "predict", "intend", "target" and similar expressions ar
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. WuXi PharmaTech to Partner with Pharmacyclics
2. Pharmacyclics Reports Third Quarter 2013 Results
3. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
4. Pharmacyclics Reports Second Quarter 2013 Results
5. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
6. Pharmacyclics Reports First Quarter 2013 Results
7. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
8. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
9. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
10. Pharmacyclics, Inc. Prices Public Offering of Common Stock
11. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)...  4WEB Medical announces the formal launch of the ... implants on the market today at this weekend,s ... Chicago .  The Osteotomy Truss System is ... with 74 size options included in one versatile set. ... 15 to 18 implant sizes, which limited a surgeon,s ...
(Date:9/19/2014)... 19, 2014 The American Association for Homecare ... and Manufacturing has joined the AAHomecare Corporate Partner Program. ... Diamond have been actively involved in AAHomecare for ... has quickly grown into a major global manufacturer of ... allows AAHomecare to increase efforts on behalf of the ...
(Date:9/19/2014)... -- Five MinuteClinic walk-in medical clinics are opening inside select CVS/pharmacy ... clinics opened in Memphis and ... added in Springfield on September 24 and ... to open October 22.  MinuteClinic is the largest and fastest growing ... . The Memphis -area clinics ...
Breaking Medicine Technology:4WEB Medical Unveils 3D-Printed Osteotomy Truss System 2Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 3
... Phase 1 Clinical Trial Results Disclosed, ... Inc., a,biopharmaceutical company developing "Best-in-Class" drugs for ... that the results,of multiple studies on its ... will be presented in eighteen presentations at ...
... CeNeRx BioPharma,Inc., a clinical stage company developing and ... system, today announced that,it has initiated a Phase ... for the treatment of major depressive disorder (MDD). ... novel class of drugs known as RIMAs,or reversible ...
Cached Medicine Technology:Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA 2Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA 3CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM) 2CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM) 3
(Date:9/21/2014)... September 21, 2014 High in the ... of disabled and able-bodied athletes rafted the Colorado River, ... ropes course in pursuit of outdoor adventure. At the ... non-profit World T.E.A.M. Sports, disabilities proved to be no ... completed the three stage event. , Each participating team ...
(Date:9/21/2014)... Developers and plugin specialist of Final ... transition plugin entitled Transpack Vol. 3 from Pixel Film ... that will add a level of professionalism to any ... Film Studios. “Blurring the line between professional and armature, ... Transpack Vol. 3 returns with over 85 all new ...
(Date:9/20/2014)... 21, 2014 Recently, iFitDress.com, a well-known wedding ... beautiful party dresses . In addition, the company has ... aim of the promotion is to benefit all of its ... its online store now. , Along with beautiful party ... items. It has recently released its new sexy short prom ...
(Date:9/20/2014)... September 20, 2014 David Cooke presented ... The first poster looked at the clinical benefits of ... for calculating diastolic function. In conjunction with colleagues at ... disease and normal LVEF by echo (>50%). Each patient ... and standard SPECT. Emory Toolbox 4.0 was ...
(Date:9/20/2014)... September 20, 2014 Ticket Down ... concert tickets. This popular ticket exchange is offering their ... Grande is nearing that next step in the entertainment business. ... superstar in the music and entertainment business, but is closing ... second straight No. 1 album, will hit the road next ...
Breaking Medicine News(10 mins):Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 2Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 3Health News:Pixel Film Studios Released Transpack Vol. 3 Plugin Exclusively for Final Cut Pro X 2Health News:Beautiful Party Dresses For Autumn Unveiled By iFitDress.com 2Health News:Versatility of Emory Toolbox 4.0 Shown at ASNC in Scientific Posters 2Health News:Versatility of Emory Toolbox 4.0 Shown at ASNC in Scientific Posters 3Health News:Ariana Grande Tickets in Chicago/Rosemont, Kansas City, Milwaukee, Saint Paul, Dallas, Houston, San Antonio, Oklahoma City Go On Sale Today 2Health News:Ariana Grande Tickets in Chicago/Rosemont, Kansas City, Milwaukee, Saint Paul, Dallas, Houston, San Antonio, Oklahoma City Go On Sale Today 3
... cancer patients treated in hospitals that care for ... so-called "high safety-net burden facilities," were significantly less ... cure the cancer compared to patients treated at ... after controlling for other factors that significantly decreased ...
... Allan Coukell, a pharmacist and director of medical programs ... Senate Health Education Labor and Pensions Committee about the ... the U.S. drug supply. Nearly 80 ... U.S. Increasingly, Americans rely on pharmaceuticals that are ...
... By Steven Reinberg HealthDay Reporter , ... the U.S. Food and Drug Administration were to meet ... bone-building drugs such as Fosamax, Actonel, Boniva and Reclast. ... to prevent fractures related to postmenopausal osteoporosis. But researchers ...
... HealthDay Reporter , THURSDAY, Sept. 8 (HealthDay News) -- Women ... somewhat more likely than teetotalers to be in good physical ... The study doesn,t prove that moderate drinking will lead to ... other factors could account for the difference. Also, the research ...
... doses of the human papillomavirus (HPV) vaccine Cervarix may be ... comes to preventive measures against cervical cancer, according to a ... of the National Cancer Institute . Across the globe, ... and HPV types 16 and 18 are a large contributor ...
... OTTAWA Sept. 8, 2011 Researchers at the ... an ancient pathway called autophagy also mobilizes and exports ... Yves Marcel, PhD, Director of the HDL Biology Laboratory, ... evolution, functions to engulf and digest cholesterol accumulated in ...
Cached Medicine News:Health News:Study finds hospitals of last resort deliver lower quality of lung cancer care 2Health News:Osteoporosis Drugs' Safety Subject of FDA Panel 2Health News:Osteoporosis Drugs' Safety Subject of FDA Panel 3Health News:For Women, Moderate Midlife Drinking Linked to Healthier Old Age 2Health News:Fewer than 3 doses of cervical cancer vaccine effective 2Health News:Researchers find process that clears cholesterol and could reverse major cause of heart attack 2
... the power of multiple technologies to ... hematology laboratory. Fluorescent detection of RNA ... Fluorescent DNA staining of nucleated red ... cell values and provides a reportable ...
... Data Management System provides comprehensive program management ... and the Precision PCx. The QC Manager ... collect, analyze, and report quality control data ... essential laboratory tool for managing data and ...
... is a one step urine test ... This test can show a "high ... which indicates whether menopause has taken ... and in a few minutes, provides ...
... simple, effective screening test which is used to ... levels which are often a warning sign of ... which requires a single drop of blood obtained ... shown in clinical trials to be 94 to ...
Medicine Products: